Data from The African-centric P47S Variant of <i>TP53</i> Confers Immune Dysregulation and Impaired Response to Immune Checkpoint Inhibition

Abstract

<div><p>The tumor suppressor <i>TP53</i> is the most frequently mutated gene in cancer and is mutationally inactivated in 50% of sporadic tumors. Inactivating mutations in <i>TP53</i> also occur in Li Fraumeni syndrome (LFS). In addition to germline mutations in <i>TP53</i> in LFS that completely inactivate this protein, there are many more germline mutant forms of <i>TP53</i> in human populations that partially inactivate this protein: we call these partially inactivating mutations “hypomorphs.” One of these hypomorphs is a SNP that exists in 6%–10% of Africans and 1%–2% of African Americans, which changes proline at amino acid 47 to serine (Pro47Ser; P47S). We previously showed that the P47S variant of p53 is intrinsically impaired for tumor suppressor function, and that this SNP is associated with increased cancer risk in mice and humans. Here we show that this SNP also influences the tumor microenvironment, and the immune microenvironment profile in P47S mice is more protumorigenic. At basal levels, P47S mice show impaired memory T-cell formation and function, along with increased anti-inflammatory (so-called “M2”) macrophages. We show that in tumor-bearing P47S mice, there is an increase in immunosuppressive myeloid-derived suppressor cells and decreased numbers of activated dendritic cells, macrophages, and B cells, along with evidence for increased T-cell exhaustion in the tumor microenvironment. Finally, we show that P47S mice demonstrate an incomplete response to anti-PD-L1 therapy. Our combined data suggest that the African-centric P47S variant leads to both intrinsic and extrinsic defects in tumor suppression.</p>Significance:<p>Findings presented here show that the P47S variant of <i>TP53</i> influences the immune microenvironment, and the immune response to cancer. This is the first time that a naturally occurring genetic variant of <i>TP53</i> has been shown to negatively impact the immune microenvironment and the response to immunotherapy.</p></div>